Open AccessA Randomized, Double-blind Evaluation of Buprenorphine Taper Duration in Primary Prescription Opioid Abusers
Author(s) -
Stacey C. Sigmon,
Kelly E. Dunn,
Kathryn A. Saulsgiver,
Mollie E. Patrick,
Gary J. Badger,
Sarah H. Heil,
John R. Brooklyn,
Stephen T. Higgins
Publication year - 2013
Publication title -
jama psychiatry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.531
H-Index - 365
eISSN - 2168-6238
pISSN - 2168-622X
DOI - 10.1001/jamapsychiatry.2013.2216
Subject(s) - buprenorphine , medicine , naltrexone , randomization , randomized controlled trial , population , opioid use disorder , abstinence , opioid , anesthesia , placebo , opioid antagonist , (+) naloxone , psychiatry , receptor , environmental health , alternative medicine , pathology
Although abuse of prescription opioids (POs) is a significant public health problem, few experimental studies have investigated the treatment needs of this growing population.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom